Xencor

Yahoo Finance • 3 days ago

We Did The Math RWJ Can Go To $54

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 25 days ago

Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts

[Wall Street New York stock exchange stock market] alexsl Erasca (NASDAQ:ERAS [https://seekingalpha.com/symbol/ERAS]), Candel Therapeutics (NASDAQ:CADL [https://seekingalpha.com/symbol/CADL]), and Xencor (NASDAQ:XNCR [https://seekingalpha... Full story

Yahoo Finance • 2 months ago

Xencor appoints biotech veteran Raymond Deshaies to board of directors

PASADENA, Calif. - Xencor, Inc. (NASDAQ:XNCR) announced Thursday the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies previously served as senior vice president of global research at Amgen Inc., where he o... Full story

Yahoo Finance • 3 months ago

Xencor director Montgomery sells shares worth $20,422

Montgomery Alan Bruce, a director at Xencor Inc (NASDAQ:XNCR), recently sold shares of the company amounting to $20,422. The transaction, which took place on June 16, 2025, involved the sale of 2,215 shares at a price of $9.22 each. This... Full story

Yahoo Finance • 3 months ago

Xencor director Gustafson sells shares worth $27,595

PASADENA, CA— Xencor Inc (NASDAQ:XNCR) Director Kurt A. Gustafson sold 2,993 shares of the company’s common stock on June 16, 2025, at an average price of $9.22 per share, totaling $27,595. The sale comes as Xencor’s stock trades near its... Full story

Yahoo Finance • last year

Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago

We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For example, after five long years the Xencor, Inc. (NASDAQ:XNCR) share price is a whole 52% lower. That is extremely sub-op... Full story

Yahoo Finance • 2 years ago

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

PASADENA, Calif., November 21, 2023--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases,... Full story

Yahoo Finance • 2 years ago

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

PASADENA, Calif., April 26, 2023--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced t... Full story

Yahoo Finance • 2 years ago

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

PASADENA, Calif., April 17, 2023--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented n... Full story

Yahoo Finance • 3 years ago

Xencor Full Year 2022 Earnings: EPS Beats Expectations

Xencor (NASDAQ:XNCR) Full Year 2022 Results Key Financial Results Revenue: US$164.6m (down 40% from FY 2021). Net loss: US$55.2m (down by 167% from US$82.6m profit in FY 2021). US$0.93 loss per share (down from US$1.42 profit in FY 2021)... Full story

Yahoo Finance • 3 years ago

Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target

SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platfo... Full story

Yahoo Finance • 3 years ago

Xencor Reports Second Quarter 2022 Financial Results

-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif., August 03, 2022--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for t... Full story

Yahoo Finance • 3 years ago

Shares of Xencor Could Be Bought on a 50% Correction

Xencor , with its protein engineering platform, is "developing a broad pipeline of drug candidates that are optimized to treat patients with cancer and autoimmune disorders". In this daily bar chart of XNCR, below, we can see that prices q... Full story

Yahoo Finance • 3 years ago

Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022

MONROVIA, Calif., April 28, 2022--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced... Full story